Altered axonal excitability properties in amyotrophic lateral sclerosis: Impaired potassium channel function related to disease stage

Brain

Volumn 129, Issue 4, 2006, Pages 953-962

  Kanai, Kazuaki ^a   Kuwabara, Satoshi ^a   Misawa, Sonoko ^a   Tamura, Noriko ^a   Ogawara, Kazue ^a   Nakata, Miho ^a   Sawai, Setsu ^a   Hattori, Takamichi ^a   Bostock, Hugh ^b  

^a CHIBA UNIVERSITY   (Japan)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

Amyotrophic lateral sclerosis; Fasciculation; Persistent sodium channel; Potassium channel; Strength duration time constant; Threshold electrotonus

Indexed keywords

POTASSIUM CHANNEL; SODIUM CHANNEL;

ADULT; AGED; AMPLITUDE MODULATION; AMYOTROPHIC LATERAL SCLEROSIS; ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE COURSE; DISEASE SEVERITY; ELECTRICITY; FASCICULATION; FEMALE; GROUPS BY AGE; HUMAN; HYPERPOLARIZATION; HYPOTHESIS; MAJOR CLINICAL STUDY; MALE; MEMBRANE DEPOLARIZATION; MOLECULAR MODEL; MUSCLE ACTION POTENTIAL; MUSCLE STRENGTH; MUSCLE TONE; NERVE EXCITABILITY; PARAMETERS OF MEASUREMENT AND ANALYSIS; PATHOPHYSIOLOGY; POTASSIUM CONDUCTANCE; PRIORITY JOURNAL; PROTEIN DEFECT; PROTEIN FUNCTION; SODIUM CONDUCTANCE; SURFACE PROPERTY; TIME PERCEPTION; WRIST;

EID: 33645075174     PISSN: 00068950     EISSN: 14602156     Source Type: Journal    
DOI: 10.1093/brain/awl024     Document Type: Article

References (51)

1. Anderson AJ, Harvey AL. Effect of the potassium channel blocking dendrotoxins on acetylcholine release and motor nerve terminal activity. Br J Pharmacol 1988; 93: 215-21.
2. Baker MD. Axonal flip-flops and oscillators. Trends Neurosci 2000; 23: 514-9.
3. + channels. Br J Pharmacol 2003; 140: 881-8.
4. Bostock H, Rothwell JC. Latent addition in motor and sensory fibres of human peripheral nerve. J Physiol 1997; 498: 277-94.
5. Bostock H, Baker M, Reid G. Changes in excitability of human motor axons underlying post-ischaemic fasciculations: evidence for two stable states. J Physiol 1991; 441: 537-57.
6. Bostock H, Sharief K, Reid G, Murray NMF. Axonal ion channel dysfunction in amyotrophic lateral sclerosis. Brain 1995; 118: 217-25.
7. Bostock H, Cikurel K, Burke D. Threshhold tracking techniques in the study of human peripheral nerve. Muscle Nerve 1998; 21: 137-58.
8. Burke D, Kiernan MC, Bostock H. Excitability of human axons. Clin Neurophysiol 2001; 112: 1575-85.
9. de Carvalho M, Swash M. Fasciculation potentials: a study of amyotrophic lateral sclerosis and other neurogenic disorders. Muscle Nerve 1998; 21: 336-44.
10. Cikurel K, Murray NMF, Bostock H. The use of threshold electrotonus in motor neurone disease. Electroencephalogr Clin Neurophysiol 1997; 103: 168.
11. Dadson PD, Billups B, Rusznak Z, Szucus G, Baker MC, Forsythe ID. Presynaptic rat Kv1.2 channels suppress synaptic terminal hyperexcitability following action potential invasion. J Physiol 2003; 550: 27-33.
12. Devaux JJ, Kleopa KA, Cooper EC, Scherer SS. KCNQ2 is a nodal K+ channel. J Neurosci 2004; 24: 1236-44.
13. Eisen A, Weber M. Treatment of amyotrophic lateral sclerosis. Drugs Aging 1999; 14: 173-96.
14. Grunnet M, Jespersen T, Angelo K, Frokjaer-Jensen C, Klaerke DA, Olesen SP, et al. Pharmacological modulation of SK3 channels. Neuropharmacology 2001; 40: 879-87.
15. Gurney ME. The use of transgenic mouse models of amyotrophic lateral sclerosis in preclinical drug studies. J Neurol Sci 1997; 152 (Suppl. 1): S67-S73.
16. Hales JP, Lin CS-Y, Bostock H. Variations in excitability of single human motor axons, related to stochastic properties of nodal sodium currents. J Physiol 2004; 559: 953-64.
17. Hjorth RJ, Walsh JC, Willison RG. The distribution and frequency of spontaneous fasciculations in motor neurone disease. J Neurol Sci 1973; 18: 469-74.
18. Horn S, Quasthoff S, Grafe P, Bostock H, Renner R, Schrank B. Abnormal axonal inward rectification in diabetic neuropathy. Muscle Nerve 1996; 19: 1268-75.
19. Jiang YM, Yamamoto M, Kobayashi Y, Yoshihira T, Liang Y, Terao S, et al. Gene expression profile of spinal cord motor neurons in sporadic amyotrophic lateral sclerosis. Ann Neurol 2005; 57: 236-51.
20. Jonas P, Koh DS, Kampe K, Hermsteiner M, Vogel W. ATP-sensitive and Ca-activated K channels in vertebrate axons: novel links between metabolism and excitability. Pflugers Arch 1991; 418: 68-73.
21. Kanai K, Kuwabara S, Arai K, Sung JY, Ogawara K, Hattori T. Muscle cramp in Machado-Joseph disease: altered motor axonal excitability properties and mexiletine treatment. Brain 2003; 126: 965-73.
22. Kiernan MC, Bostock H. Effects of membrane polarization and ischemia on the excitability properties of human motor axons. Brain 2000; 123: 2542-51.
23. Kiernan MC, Burke D. Threshold electrotonus in the assessment of motor neuron disease. In: Eisen A, editor. Clinical Neurophysiology of Motor Neuron Diseases. Handbook of Clinical Neurophysiology. Amsterdam: Elsevier, 2005. p. 399-409.
24. Kiernan MC, Burke D, Andersen K, Bostock H. Multiple measures of axonal excitability: a new approach in clinical testing. Muscle Nerve 2000; 23: 399-409.
25. Kiernan MC, Cikurel K, Bostock H. Effects of temperature on the excitability properties of human motor axons. Brain 2001a; 124: 816-25.
26. Kiernan MC, Hart IK, Bostock H. Excitability properties of motor axons in patients with spontaneous motor unit activity. J Neurol Neurosurg Psychiatry 2001b; 70: 56-64.
27. Kiernan MC, Guglielmi JM, Kaji R, Murray NM, Bostock H. Evidence for axonal membrane hyperpolarization in multifocal motor neuropathy with conduction block. Brain 2002; 125: 664-75.
28. Kiernan MC, Isbister GK, Lin CS, Burke D, Bostock H. Acute tetrodotoxin-induced neurotoxicity after ingestion of puffer fish. Ann Neurol 2005; 57: 339-48.
29. Kitano Y, Kuwabara S, Misawa S, Ogawara K, Kanai K, Kikkawa Y, et al. The acute effects of glycemic control on axonal excitability in human diabetics. Ann Neurol 2004; 56: 462-7.
30. Koh D-S, Jonas P, Bräu M, Vogel W. A TEA-insensitive flickering potassium channel active around the resting potential in myelinated nerve. J Membr Biol 1992; 130: 149-62.
31. + channels localized in the nodal region of myelinated axons of Xenopus. J Physiol 1994; 479: 183-97.
32. Kriz J, Gowing G, Julien JP. Efficient three-drug cocktail for disease induced by mutant superoxide dismutase. Ann Neurol 2003; 53: 429-36.
33. Kuo JJ, Siddique T, Fu R, Heckman CJ. Increased persistent Na(+) current and its effect on excitability in motoneurones cultured from mutant SOD1 mice. J Physiol 2005; 563: 843-54.
34. Kuwabara S, Cappelen-Smith C, Lin CS, Mogyoros I, Burke D. Excitability properties of median and peroneal motor axons. Muscle Nerve 2000; 23: 1365-73.
35. Kuwabara S, Ogawara K, Sung J-Y, Mori M, Kannai K, Hattori T, et al. Differences in membrane properties of axonal and demyelinating Guillain-Barre syndromes. Ann Neurol 2002; 52: 180-7.
36. Lacomblez L, Bensimon G, Leigh PN, Guillet P, Meininger V. Dose-ranging study of riluzole in amyotrophic lateral sclerosis. Amyotrophic Lateral Sclerosis/Riluzole Study Group II. Lancet 1996; 347: 1425-31.
37. LaMonte BH, Wallace KE, Holloway BA, Shelly SS, Ascano J, Tokito M, et al. Disruption of dynein/dynactin inhibits axonal transport in motor neurons causing late-onset progressive degeneration. Neuron 2002; 34: 715-27.
38. Layzer RB. The origin of muscle fasciculations and cramps. Muscle Nerve 1994; 17: 1243-9.
39. Liveson JA, Ma DM. Median nerve (motor). In: Liveson JA, Ma DM, editors, Laboratory reference for clinical neurophysiology. FA Davis: Philadelphia; 1992. p. 92-98.
40. Mogyoros I, Kiernan M, Burke D, Bostock H. Strength-duration properties of sensory and motor axons in amyotrophic lateral sclerosis. Brain 1998; 121: 851-9.
41. Morrison KE. Therapies in amyotrophic lateral sclerosis beyond riluzole. Curr Opin Pharmacol 2002; 2: 302-9.
42. Press WH, Teukolsky SA, Vetterling WT, Flannery BP. Numerical recipes in C - the art of scientific computing. Cambridge: Cambridge University Press; 1992. p. 707-24.
43. Rekling JC. Neuroprotective effects of anticonvulsants in rat hippocampal slice cultures exposed to oxygen/glucose deprivation. Neurosci Lett 2003; 335: 167-70.
44. Rowland LP, Shneider NA. Amyotrophic lateral sclerosis. N Engl J Med 2001; 344: 1688-700.
45. Schwarz JR, Reid G, Bostock H. Action potentials and membrane currents in the human node of Ranvier. Pflugers Arch 1995; 430: 283-92.
46. Urbani A, Belluzzi O. Riluzole inhibits persistent sodium current in mammalian CNS neurons. Eur J Neurosci 2000; 12: 3567-74.
47. Wang H, Zhang YL, Tang XC, Feng HS, Hu G. Targeting ischemic stroke with a novel opener of ATP-sensitive potassium channels in the brain. Mol Pharmacol 2004; 66: 1160-8.
48. Wickenden AD. Potassium channels as anti-epileptic drug targets. Neuropharmacology 2002; 43: 1055-60.
49. Wiedemann FR, Manfredi G, Mawrin C, Beal MF, Schon EA. Mitochondrial DNA and respiratory chain function in spinal cords of ALS patients. J Neurochem 2002; 80: 616-25.
50. World Federation of Neurology Research Group on Neuromuscular Disease. El Escorial World Federation of Neurology criteria for the diagnosis of amyotrophic lateral sclerosis. J Neurol Sci 1994; 124 (Suppl.): 96-107.
51. Xu L, Enyeart JA, Enyeart JJ. Neuroprotective agent riluzole dramatically slows inactivation of Kv1.4 potassium channels by a voltage-dependent oxidative mechanism. J Pharmacol Exp Ther 2001; 299: 227-37.